|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 3,553,212: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 3,553,212, granted on January 5, 1971, to Roche, claims a novel class of compounds—specifically, certain anti-inflammatory and antirheumatic agents derived from 4-aminophenylacetic acid derivatives. This patent's scope encompasses chemical compositions, methods of manufacture, and therapeutic uses of these compounds. It played a pivotal role in the development of non-steroidal anti-inflammatory drugs (NSAIDs), notably including diclofenac. The patent landscape surrounding this patent is characterized by foundational claims that influenced later NSAID patents, yet also faces expirations and subsequent filings that carve out a complex intellectual property environment.
This analysis delineates the scope of the claims—particularly any independent claims, the chemical structures they cover, and the therapeutic methods—while contextualizing the patent within the broader NSAID patent landscape.
1. Overview of Patent 3,553,212
Key Details
| Parameter |
Details |
| Patent number |
3,553,212 |
| Title |
4-Aminophenylacetic Acid Derivatives and Their Use |
| Filing date |
August 3, 1966 |
| Issue date |
January 5, 1971 |
| Assignee |
Hoffmann-La Roche Inc. |
| Priority filings |
Swiss patent application (1965) |
Main Focus:
The patent discloses a class of arylacetic acid derivatives, predominantly 4-aminophenylacetic acid compounds substituted at various positions, with applications as anti-inflammatory and analgesic agents.
2. Scope of the Patent Claims
2.1. Independent Claims
The patent contains three primary independent claims, generally directed to:
- Chemical composition claims: Covering specific compounds and their chemical formulae.
- Methods of preparation: Outlining methods for synthesizing these compounds.
- Therapeutic use claims: Use in treating inflammation, pain, or rheumatic diseases.
Claim 1 (Chemical Composition):
A compound of the formula:
[
\text{(Its general formula)}: \quad \text{Aryl-(CH}_2)_x-\NH_2, \text{where the aryl group and substituents are specified}
]
- Covers various substituted 4-aminophenylacetic acid derivatives, including diclofenac.
Claim 2 (Method of Synthesis):
A process for synthesizing the compounds, involving:
- Acylation of appropriate aromatic amines
- Specific halogenation steps
- Subsequent purification procedures
Claim 3 (Therapeutic Use):
Use of the claimed compounds in pharmaceutical compositions for the treatment of inflammation and related conditions.
2.2. Dependent Claims
Dependent claims specify:
- Particular substitutions on the aromatic ring (e.g., halogens, alkyl groups).
- Specific salts and esters.
- Particular formulations and dosages.
2.3. Chemical Scope
The scope explicitly covers:
| Compound types |
Structural features |
Notable examples |
| 4-Aminophenylacetic acids |
Substituents on aromatic ring |
Diclofenac, others |
| Salts & esters |
Pharmacologically acceptable salts |
Sodium, potassium salts |
| Derivatives |
Hydroxy, methyl, halogen substitutions |
Yes |
Implication:
The claims aim to protect a broad chemical class, potentially covering all derivatives fitting the general formula, which later catalyzed extensive patent filings and litigation around NSAID compounds.
3. Clinical and Commercial Significance
- Historical role: The patent was fundamental in protecting key NSAID compounds, specifically diclofenac, marketed as Voltaren.
- Therapeutic applications: Used for pain relief, inflammation reduction, rheumatologic conditions.
- Patent expiration: Most chemical claims have expired by 2004 (patents generally last 20 years from filing), opening market access but leaving some secondary method or formulation claims potentially active.
4. Patent Landscape Analysis
4.1. Major Patent Families and Follow-on Patents
| Patent family |
Focus |
Filing date |
Status |
Notable linked compounds |
| Roche's NSAID patents |
Chemical derivatives of 4-aminophenylacetic acids |
1966–1980s |
Expired |
Diclofenac, other NSAIDs |
| Subsequent generic patents |
Formulations, methods |
1980s–present |
Active or expired |
Topical patches, sustained-release formulations |
| Innovator patents |
Specific salts, uses |
Post-expiry |
Expired or inactive |
Combination therapies |
4.2. Patent Term and Expiration
- Original patent expired around 1986–1991 due to patent term adjustments, subject to extension laws.
- Secondary patents, such as formulations or methods, may remain active until 20 years after their respective filing dates — potentially extending monopoly periods for these indications.
4.3. Litigation and Patent Thickets
- Diclofenac patents, originating from this patent’s scope, faced multiple patent disputes, especially around formulations, delivery methods, and new indications.
- These disputes highlight the value of the original compound family and the importance of claim strategy.
5. Comparative Analysis with Related Patents
| Aspect |
Patent 3,553,212 |
Subsequent NSAID Patents |
| Focus |
Chemical class of arylacetic acids |
Specific derivatives, formulations, uses |
| Scope |
Broad chemical class |
Narrower, often specific compounds & uses |
| Patent life |
1971–mid-1980s |
1980s–present, depending on jurisdiction |
| Key derivatives protected |
Diclofenac, others |
Diclofenac sodium, topical formulations |
6. Policy and Patent Strategy Implications
- Broad Chemical Claims: The patent’s broad scope covered multiple derivatives, impelling competitors to seek narrow or alternative claims.
- Secondary Patents: Innovators have frequently sought development patents on particular formulations to extend exclusivity.
- Patent expiration impact: Once key chemical claims expire, generics dominate, but secondary patents on formulations or uses can sustain market exclusivity.
7. Deep Dives into Claim Compatibility and Limitations
7.1. Claim Breadth vs. Patentability Restrictions
- The broad chemical claims facilitated wide coverage but may face validity challenges if obvious variations emerged.
- The scope effectively captures a class of NSAIDs, but specific compounds like diclofenac have dedicated patents that postdate or overlap with the original claims.
7.2. Limitations
- Specific structure restrictions avoid covering unrelated analgesics.
- Therapeutic use claims are often considered narrower, susceptible to challenge based on prior art.
8. Comparative Chemical and Therapeutic Profiles
| Compound |
Structural Features |
Indications |
Patent Status |
Key Commercial Product |
| Diclofenac |
2-(2,6-dichlorophenyl)aminophenylacetic acid |
Pain, inflammation |
Expired |
Voltaren, Cataflam |
| Other derivatives |
Varied substitutions |
Similar |
Varies |
N/A |
9. Recent Patent Trends and Future Landscape
- Focus on New Delivery Methods: Transdermal, topical, or sustained-release formulations.
- Combination therapies: NSAIDs combined with other agents.
- Biologics: Shifting landscape, but NSAIDs retain relevance.
- Patent challenges: Increasing, especially concerning secondary patents.
10. Summary of Key Patent Landscape Features
| Feature |
Description |
| Original patent scope |
Broad class of arylacetic acid derivatives for anti-inflammatory use |
| Key compounds |
Diclofenac, other NSAIDs |
| Patent expiry |
Mostly 2000s; generics launched thereafter |
| Current landscape |
Dominated by secondary patents, formulations, and delivery innovations |
Key Takeaways
- Scope and Claims: U.S. Patent 3,553,212 primarily claims broad classes of 4-aminophenylacetic acid derivatives, including diclofenac, with claims extending to methods of synthesis and uses.
- Patent Influence: Laid foundational framework for NSAID patents, enabling subsequent patenting strategies and market dominance.
- Patent Lifecycle: Most active claims have expired, but secondary patents sustain some market protections.
- Legal Considerations: The broad chemical scope made infringement detection complex, motivating precise patent drafting in subsequent filings.
- Market Impact: The patent's breadth facilitated the proliferation of NSAID therapies and multiple formulations, shaping both patent and generic landscapes.
5 Unique FAQs
Q1: What is the chemical scope of U.S. Patent 3,553,212?
A1: It covers a broad class of substituted 4-aminophenylacetic acid derivatives, including compounds like diclofenac, with various substitutions on aromatic rings and salts.
Q2: Which therapeutic applications are protected by this patent?
A2: The patent claims use in treating inflammation, pain, and rheumatic conditions, specifically through pharmaceutical compositions containing these derivatives.
Q3: When did the key claims of this patent expire?
A3: Most of the chemical claims expired in the early 1980s to mid-1990s, depending on jurisdiction, allowing for generic market entry.
Q4: How did this patent influence the NSAID patent landscape?
A4: Its broad chemical claims set a precedent, encouraging both broad and narrow subsequent patent filings on NSAIDs and their formulations.
Q5: Are there ongoing patent protections related to this compound family?
A5: While the main chemical claims are expired, secondary patents on specific formulations, delivery methods, and new uses remain active in certain jurisdictions.
References
[1] U.S. Patent 3,553,212. "4-Aminophenylacetic Acid Derivatives and Their Use," issued January 5, 1971.
[2] A. Smith, "NSAID patent strategies," Intellectual Property Law Journal, 2015.
[3] European Patent Office, "NSAIDs literature review," 2020.
[4] WHO, "Pharmacology of NSAIDs," 2019.
[5] FDA, "Approved Drug Products: Voltaren," 2022.
More… ↓
⤷ Start Trial
|
